Telik Initiates Telintra Phase 2b Clinical Trial

The primary objective of the trial is to determine the hematologic improvement-erythroid response rate as determined by clinically significant transfusion reduction or independence.

U.S. clinical stage drug developer Telik, Inc. announced Thursday the initiation of a Phase 2b clinical trial to evaluate Telintra treatment of patients with Low to Intermediate-1 IPSS Risk, transfusion dependent, non-deletion (5q) myelodysplastic syndrome (MDS), who have not been treated with hypomethylating agents (HMA). 

This multicenter trial is intended to enroll up to 145 evaluable patients with 2 planned interim analyses, the first of which will be performed when data from 49 evaluable patients are available; and the second at 97 evaluable patients.

The primary objective of the trial is to determine the hematologic improvement-erythroid response rate as determined by clinically significant transfusion reduction or independence, in accordance with Int